Brian Riley - Beam Therapeutics VP Operations
| BEAM Stock | USD 27.62 1.67 5.70% |
Insider
Brian Riley is VP Operations of Beam Therapeutics
| Age | 48 |
| Phone | 857 327 8775 |
| Web | https://beamtx.com |
Brian Riley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Riley against Beam Therapeutics stock is an integral part of due diligence when investing in Beam Therapeutics. Brian Riley insider activity provides valuable insight into whether Beam Therapeutics is net buyers or sellers over its current business cycle. Note, Beam Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Beam Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Riley over a year ago Acquisition by Brian Riley of 50000 shares of Global Indemnity at 30.0 subject to Rule 16b-3 |
Beam Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2348) % which means that it has lost $0.2348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4719) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Barry MD | Immunitybio | 61 | |
| Brian MBA | Agios Pharm | 57 | |
| Craig MD | Agios Pharm | 73 | |
| Linda Higgins | Arcus Biosciences | N/A | |
| Sandeep MD | Immunitybio | N/A | |
| Alexander MD | Denali Therapeutics | 52 | |
| Erin Schellhammer | Cogent Biosciences | N/A | |
| Jeffrey Hager | Ideaya Biosciences | 59 | |
| Helen Luu | Immunitybio | N/A | |
| Richa Poddar | Agios Pharm | 42 | |
| Marc TessierLavigne | Denali Therapeutics | 65 | |
| Nicole Lambert | Arcus Biosciences | 46 | |
| Sofie Gijsel | Galapagos NV ADR | N/A | |
| John Montana | Galapagos NV ADR | N/A | |
| Marieke Vermeersch | Galapagos NV ADR | N/A | |
| Blake Borgeson | Recursion Pharmaceuticals | 43 | |
| Michael Quigley | Arcus Biosciences | 38 | |
| Ryan Kelly | Recursion Pharmaceuticals | N/A | |
| Cecilia Jones | Agios Pharm | 51 | |
| Matthew MD | Ideaya Biosciences | N/A | |
| Sara Saltzman | Cogent Biosciences | N/A | |
Management Performance
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 |
Beam Therapeutics Leadership Team
Elected by the shareholders, the Beam Therapeutics' board of directors comprises two types of representatives: Beam Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Beam. The board's role is to monitor Beam Therapeutics' management team and ensure that shareholders' interests are well served. Beam Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Beam Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Manmohan Singh, Chief Officer | ||
| Nicole Gaudelli, CoFounder | ||
| Brian Riley, VP Operations | ||
| Susan OConnor, Chief Officer | ||
| Alexis Komor, CoFounder | ||
| Amy MD, Chief Officer | ||
| Anne Woodland, Senior Affairs | ||
| Suzanne Fleming, Chief Officer | ||
| Sravan Emany, Chief Officer | ||
| TerryAnn MBA, CFO Treasurer | ||
| Giuseppe Ciaramella, Pres Officer | ||
| David Liu, CoFounder | ||
| Feng Zhang, CoFounder | ||
| John MBA, CEO Director | ||
| Guiseppe Ciaramella, President | ||
| Bethany Cavanagh, Senior Treasurer | ||
| Gopi Shanker, Chief Officer | ||
| John Lo, Chief Officer | ||
| Holly Manning, Vice Communications | ||
| Dr JD, Chief VP |
Beam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Beam Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (13.08) % | |||
| Current Valuation | 2.05 B | |||
| Shares Outstanding | 101.47 M | |||
| Shares Owned By Insiders | 1.23 % | |||
| Shares Owned By Institutions | 98.77 % | |||
| Number Of Shares Shorted | 20.04 M | |||
| Price To Earning | 37.48 X | |||
| Price To Book | 2.90 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Stock sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.